Johanna Bendell is Chief Development Officer, Oncology at Pfizer. OpenAlex indexes 928 publications with 30,947 citations (h-index 83); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Johanna C. Bendell, MD, is Chief Development Officer, Oncology at Pfizer. The public record shows 928 publications with 30,947 citations (h-index 83), centered on Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 5 companies.
- Most recent indexed publication: 2025 · Molecular cancer therapeutics
- Top research focus: Colorectal Cancer Treatments and Studies
- 20 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 350.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Sponsor: Evelo Biosciences, Inc.
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
Sponsor: AstraZeneca
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:
- ITI, Inc.Program year20221 payment
- Roche TCRC, Inc.Program year20211 payment$31,020openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20211 payment
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroid100%Dexamethasone sodium phosphate97%Dexamethasone3%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
310 congress contributions (2006–2021) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.
ASCO Annual Meeting
ASCO2021Presenting authorPosterTrials in progress
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors.
Molecular cancer therapeutics
Clinical Trial2025 - Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Clinical cancer research
Clinical Trial2022
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/johanna-bendell-2324b3126
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Johanna-C-Bendell-38147769
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/johanna-bendell-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/sarahcannonresearch/posts/dr-johanna-bendell-moderates-a-peer-exchange-with-fellow-experts-to-discuss-diff/5782503338430255
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
sarahcannon.com/about/leadership/johanna-bendell
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sarahcannon.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Hematology and Medical Oncology, Dana-Farber Cancer Institute / Massachusetts General Hospital
2003verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lifesciencewa.org ↗
Editorial & leadership roles
journal and society appointments- Chief Development Officer
Oncology, Pfizer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pharmaphorum.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →endpoints.news ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lifesciencewa.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lifesciencewa.org ↗
- Formerly Director
Drug Development Unit and Gastrointestinal Oncology Program, Sarah Cannon Research Institute, Nashville, TN
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lifesciencewa.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pharmaphorum.com ↗
- Featured guest
Pfizer's "Science Will Win" podcast, Season 6 Episode 1: "The Alarming Rise of Early-onset Cancer"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pfizer.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ariel Feldstein, MD
Pfizer
Alejandra Gurtman, MD
Pfizer
Ruth Bailey
Pfizer
Elaine Thomas
Pfizer